Sulfunol 500 Tablet 15

Sulfunol 500 Tablet 15 should only be used during pregnancy if clearly advised by your doctor. High doses may reduce folate absorption, which is important for foetal development. Supplementation may be required.
 

Sulfasalazine passes into breast milk. Use during breastfeeding is not generally recommended, as it may cause diarrhoea or blood-related issues in the infant. Consult your doctor before use.
 

Alcohol can irritate the stomach and worsen gastrointestinal side effects such as nausea or indigestion caused by Sulfunol 500 Tablet 15. Limiting or avoiding alcohol is advisable during treatment.
 

Patients with liver disease must exercise caution, as Sulfunol 500 Tablet 15 can increase liver enzyme levels. Regular monitoring of liver function tests is necessary.
 

As Sulfunol 500 Tablet 15 may affect kidney function and increase the risk of kidney stones, it should be used with caution in patients with kidney disease. Adequate hydration is strongly advised.
 

Sulfunol 500 Tablet 15 generally does not impair alertness. However, if you feel dizzy or unwell, avoid driving, cycling, or operating heavy machinery.
 

Do not take Sulfunol 500 Tablet 15 if you are allergic to sulfasalazine, sulphonamides, salicylates, or any component of the tablet. Severe allergic reactions such as rash, swelling, or breathing difficulty require immediate medical attention.
 

Sulfunol 500 Tablet 15 can be used in children above 6 years of age when prescribed.
 

Older patients may be more prone to blood disorders, kidney impairment, or liver issues while on Sulfunol 500 Tablet 15. Closer monitoring is required in this age group.

Sulfunol 500 Tablet 15 interacts with the following medicines:

• Blood thinners (warfarin): The concomitant use may increase the risk of bleeding.
• Digoxin (heart medicine): The concomitant use may reduce absorption and effectiveness.
• Iron and folic acid supplements: The concomitant use may reduce absorption; supplementation may be required.
• Antidiabetic medicines (glimepiride, glyburide, glipizide): The concomitant use may enhance hypoglycaemic effect.
• Methotrexate (arthritis/cancer treatment): The concomitant use may increase risk of toxicity.
• Azathioprine and mercaptopurine (immune-suppressing agents): The concomitant use may increase risk of bone marrow suppression.
• Isoniazid (anti-tuberculosis medicine): The concomitant use may increase risk of liver damage.
• Methenamine (antibiotic): The concomitant use may reduce effectiveness of this medicine.